 |
Temoporfin |
|---|---|
| Trade Name | Foscan |
| Orphan Indication | Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy |
| USA Market Approval | USA |
| USA Designation Date | 1999-10-28 00:00:00 |
| Sponsor | Biolitec Pharma Ireland Ltd.;United Drug House, Dublin; |
